ALNY
Price
$418.91
Change
-$0.00 (-0.00%)
Updated
Aug 6 closing price
Capitalization
56.12B
77 days until earnings call
SGMO
Price
$0.53
Change
-$0.00 (-0.00%)
Updated
Aug 6 closing price
Capitalization
130.04M
Earnings call today
Interact to see
Advertisement

ALNY vs SGMO

Header iconALNY vs SGMO Comparison
Open Charts ALNY vs SGMOBanner chart's image
Alnylam Pharmaceuticals
Price$418.91
Change-$0.00 (-0.00%)
Volume$435
Capitalization56.12B
Sangamo Therapeutics
Price$0.53
Change-$0.00 (-0.00%)
Volume$4.3M
Capitalization130.04M
ALNY vs SGMO Comparison Chart in %
Loading...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGMO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALNY vs. SGMO commentary
Aug 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Buy and SGMO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 07, 2025
Stock price -- (ALNY: $428.14 vs. SGMO: $0.53)
Brand notoriety: ALNY and SGMO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 122% vs. SGMO: 72%
Market capitalization -- ALNY: $56.12B vs. SGMO: $130.04M
ALNY [@Biotechnology] is valued at $56.12B. SGMO’s [@Biotechnology] market capitalization is $130.04M. The market cap for tickers in the [@Biotechnology] industry ranges from $210.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 1 FA rating(s) are green whileSGMO’s FA Score has 0 green FA rating(s).

  • ALNY’s FA Score: 1 green, 4 red.
  • SGMO’s FA Score: 0 green, 5 red.
According to our system of comparison, ALNY is a better buy in the long-term than SGMO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 4 TA indicator(s) are bullish while SGMO’s TA Score has 5 bullish TA indicator(s).

  • ALNY’s TA Score: 4 bullish, 4 bearish.
  • SGMO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ALNY and SGMO are a good buy in the short-term.

Price Growth

ALNY (@Biotechnology) experienced а +26.00% price change this week, while SGMO (@Biotechnology) price change was -2.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.54%. For the same industry, the average monthly price growth was +12.42%, and the average quarterly price growth was +13.42%.

Reported Earning Dates

ALNY is expected to report earnings on Oct 23, 2025.

SGMO is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (-0.54% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($56.1B) has a higher market cap than SGMO($130M). ALNY YTD gains are higher at: 81.947 vs. SGMO (-48.049). SGMO has higher annual earnings (EBITDA): -72.14M vs. ALNY (-170.84M). ALNY has more cash in the bank: 2.86B vs. SGMO (25.2M). SGMO has less debt than ALNY: SGMO (24.9M) vs ALNY (1.3B). ALNY has higher revenues than SGMO: ALNY (2.46B) vs SGMO (63.8M).
ALNYSGMOALNY / SGMO
Capitalization56.1B130M43,154%
EBITDA-170.84M-72.14M237%
Gain YTD81.947-48.049-171%
P/E RatioN/AN/A-
Revenue2.46B63.8M3,859%
Total Cash2.86B25.2M11,341%
Total Debt1.3B24.9M5,209%
FUNDAMENTALS RATINGS
ALNY vs SGMO: Fundamental Ratings
ALNY
SGMO
OUTLOOK RATING
1..100
2169
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
11100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3765
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SGMO's Valuation (79) in the Biotechnology industry is in the same range as ALNY (97). This means that SGMO’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's Profit vs Risk Rating (11) in the Biotechnology industry is significantly better than the same rating for SGMO (100). This means that ALNY’s stock grew significantly faster than SGMO’s over the last 12 months.

ALNY's SMR Rating (100) in the Biotechnology industry is in the same range as SGMO (100). This means that ALNY’s stock grew similarly to SGMO’s over the last 12 months.

ALNY's Price Growth Rating (37) in the Biotechnology industry is in the same range as SGMO (65). This means that ALNY’s stock grew similarly to SGMO’s over the last 12 months.

ALNY's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SGMO (100). This means that ALNY’s stock grew similarly to SGMO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYSGMO
RSI
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 8 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
62%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 14 days ago
74%
Declines
ODDS (%)
Bearish Trend 17 days ago
65%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGMO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VNM17.090.42
+2.52%
VanEck Vietnam ETF
VSGX65.890.38
+0.58%
Vanguard ESG International Stock ETF
LSVD26.220.13
+0.49%
LSV Disciplined Value ETF
ADPV40.160.01
+0.03%
Adaptiv™ Select ETF
IBIH26.32N/A
-0.02%
iShares iBonds Oct 2031 Term Tips ETF